CN115025078A - Application of longan pomace polyphenol extract in preparation of medicine for preventing and treating non-alcoholic steatohepatitis - Google Patents
Application of longan pomace polyphenol extract in preparation of medicine for preventing and treating non-alcoholic steatohepatitis Download PDFInfo
- Publication number
- CN115025078A CN115025078A CN202210575399.0A CN202210575399A CN115025078A CN 115025078 A CN115025078 A CN 115025078A CN 202210575399 A CN202210575399 A CN 202210575399A CN 115025078 A CN115025078 A CN 115025078A
- Authority
- CN
- China
- Prior art keywords
- longan
- polyphenol extract
- pomace
- preventing
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000000235 Euphoria longan Nutrition 0.000 title claims abstract description 99
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 83
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 83
- 239000000284 extract Substances 0.000 title claims abstract description 64
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 49
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims description 22
- 244000139609 Euphoria longan Species 0.000 title 1
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 98
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940074391 gallic acid Drugs 0.000 claims abstract description 11
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 235000013399 edible fruits Nutrition 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 10
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 claims description 5
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 claims description 5
- 239000003094 microcapsule Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 150000003254 radicals Chemical class 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 5
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 claims 1
- 230000007760 free radical scavenging Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 abstract description 11
- 230000014509 gene expression Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 abstract description 6
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 abstract description 6
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 abstract description 6
- 229940126902 Phlorizin Drugs 0.000 abstract description 6
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 abstract description 6
- 235000012734 epicatechin Nutrition 0.000 abstract description 6
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 abstract description 6
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 abstract description 6
- 235000019139 phlorizin Nutrition 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 102000004311 liver X receptors Human genes 0.000 abstract description 5
- 108090000865 liver X receptors Proteins 0.000 abstract description 5
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 abstract description 4
- 102000023984 PPAR alpha Human genes 0.000 abstract description 4
- 108010028924 PPAR alpha Proteins 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- NLAWPKPYBMEWIR-SKYQDXIQSA-N (2S)-poncirin Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 NLAWPKPYBMEWIR-SKYQDXIQSA-N 0.000 abstract description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 abstract description 3
- FCXRFTLSXMRXTM-UHFFFAOYSA-N 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-2,3-dihydrochromen-4-one Chemical compound C1C(=O)C2=C(O)C(OC)=C(O)C=C2OC1C1=CC=C(O)C=C1 FCXRFTLSXMRXTM-UHFFFAOYSA-N 0.000 abstract description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 abstract description 3
- NLAWPKPYBMEWIR-VGQRFNKBSA-N Poncirin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 NLAWPKPYBMEWIR-VGQRFNKBSA-N 0.000 abstract description 3
- 229920002982 Procyanidin A2 Polymers 0.000 abstract description 3
- 229920000385 Procyanidin B1 Polymers 0.000 abstract description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 abstract description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 abstract description 3
- 229940114124 ferulic acid Drugs 0.000 abstract description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 abstract description 3
- 235000001785 ferulic acid Nutrition 0.000 abstract description 3
- OETSANFHEJPBHW-UHFFFAOYSA-N hispidulin Natural products COc1cc2c(cc1O)oc(cc2=O)-c1ccc(O)cc1 OETSANFHEJPBHW-UHFFFAOYSA-N 0.000 abstract description 3
- NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 abstract description 3
- NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 abstract description 3
- XFZJEEAOWLFHDH-UKWJTHFESA-N procyanidin B1 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UKWJTHFESA-N 0.000 abstract description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 abstract description 3
- 235000005493 rutin Nutrition 0.000 abstract description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 abstract description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 abstract description 3
- 229960004555 rutoside Drugs 0.000 abstract description 3
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 abstract description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 230000001276 controlling effect Effects 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 16
- 235000009200 high fat diet Nutrition 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- -1 DPPH free radical Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000000636 white adipocyte Anatomy 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000006372 lipid accumulation Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000009412 basement excavation Methods 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101150075266 CYP7A1 gene Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101150079919 Cyp27a1 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
Abstract
The invention provides application of a longan pomace polyphenol extract in preparing a medicine for preventing and treating non-alcoholic steatohepatitis. The longan pomace polyphenol extract has clear polyphenol composition: gallic acid, procyanidin B, epicatechin, procyanidin A2, syringic acid, 4-hydroxycinnamic acid, poncirin, ferulic acid, rutin, phlorizin and 6-methoxynaringenin. The longan pomace polyphenol extract provided by the invention has the effect of increasing LXR and PPAR alpha expression, so that the longan pomace polyphenol extract can play a role in reducing blood fat by regulating and controlling the expression of genes related to lipid catabolism and transportation, and has a clear lipid-reducing mechanism.
Description
Technical Field
The invention belongs to a new medical application of a longan pomace polyphenol extract, and particularly relates to an application of a longan pomace polyphenol extract in preparation of a medicine for preventing and treating non-alcoholic steatohepatitis.
Background
Non-alcoholic fatty liver disease (NAFLD) refers to a pathological syndrome characterized mainly by excessive deposition of fat in the liver and inflammatory reaction, in addition to alcohol and other definite liver injury factors (hepatitis virus, drugs, autoimmunity, etc.). NAFLD is classified into simple fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic fibrosis, cirrhosis and liver cancer according to its development process. At present, the global prevalence rate of NAFLD is about 25%, the number of NAFLD patients in China is increased from 18% to nearly 30% within 10 years, and by 2030, China becomes the country with the fastest global prevalence rate of NAFLD. NAFLD not only increases the risk of liver-related diseases, but also is an important risk factor for metabolic syndrome, atherosclerosis and colorectal cancer, and has become a public health problem that seriously threatens human health. Wherein, NASH accounts for 10% -30% of NAFLD, is an important intermediate link for the simple fatty liver to progress to hepatic fibrosis, liver cirrhosis and liver cancer, but no specific medicine for treating NASH exists clinically. Therefore, the excavation of natural bioactive substances without side effects that retard and block the progression of NASH becomes an urgent problem to be solved.
The exact pathogenesis of NASH has not been fully elucidated, but it is clear that the accumulation of lipids in hepatocytes and the interaction of their inflammatory response, cellular stress and apoptosis promote the development of NASH. Lipid accumulation in the liver is the central mechanism for the onset of NASH, and fat deposition is a major feature of NASH. Liver steatosis is caused by imbalance between lipid synthesis and utilization, including free fatty acid uptake, de novo fatty acid synthesis, fatty acid oxidation, triglyceride output and the like, and abnormal in any link can affect liver lipid accumulation, thereby causing the occurrence and development of NASH. Therefore, regulating liver lipid metabolism is an important means of preventing NASH.
Longan is also commonly called as longan, is a plant with homology of medicine and food, is a good nourishing product, has higher medicinal value and has important research significance. The medicinal value of longan is closely related to the abundant polyphenols contained in the longan, and the existing researches find that longan fruits contain abundant polyphenols, particularly, the types and the contents of the polyphenols in longan peels and seeds are far higher than those of longan pulp. At present, most of researches focus on identification, separation and purification of polyphenols in longan pulp and differential analysis of polyphenols in different varieties of longan fruits. However, the deep excavation and functional evaluation research of the abundant polyphenols in the longan pomace is less. Longan is used as a folk medicine in traditional medicine for arresting sweating, stopping bleeding and treating insomnia and other symptoms. Modern researches find that longan has important biological activities of resisting oxidation, reducing blood sugar, resisting tumors, regulating immune system and the like.
However, the effect of longan polyphenol on NASH has not been reported so far.
Disclosure of Invention
In view of the above-mentioned shortcomings in the prior art, the present invention aims to provide an application of a longan pomace polyphenol extract in the preparation of a drug for preventing and treating non-alcoholic steatohepatitis, wherein the longan pomace polyphenol extract has a definite composition and can be used as a drug ingredient and/or a food nutritional factor for effectively interfering in NASH.
In order to achieve the purpose, the invention provides the following technical scheme: application of longan pomace polyphenol extract in preparation of medicine for preventing and treating non-alcoholic steatohepatitis is provided.
Further, the longan pomace polyphenol extract is powdery.
Further, the medicine is an oral preparation.
Further, the medicine is a tablet, a microcapsule, a pill or powder.
Further, the dosage of the medicine is 200 mg/kg.
The longan pomace polyphenol extract is prepared by the following method:
(1) drying longan fruit residues at 45-55 deg.C for 36-48h, and pulverizing with ultra-high speed pulverizer to obtain longan fruit residue powder;
(2) adding the longan pulp powder into 80 mass percent ethanol, and homogenizing for 2min at the rotation speed of 5000-; extracting with ultrasonic wave for 30min, and collecting filtrate;
(3) extracting the above residue for 2 times, and collecting filtrates respectively;
(4) combining the filtrates collected in step (2) and step (3), and concentrating the collected filtrates at 40-45 deg.C under 10-100mbar under reduced pressure to obtain concentrated solution A;
(5) adding ethyl acetate into the concentrated solution A, stirring for 20-30min, and standing in a separating funnel until obvious layering occurs;
(6) concentrating the upper layer at 40-45 deg.C under 10-100mbar under reduced pressure to obtain concentrated solution B;
(7) and (3) drying the concentrated solution B in vacuum freeze drying to obtain the longan pomace polyphenol extract.
Further, the total polyphenol content of the longan pomace polyphenol extract is not less than 700mg gallic acid equivalent/g.
Further, the elimination rate of DPPH free radical by the longan pomace polyphenol extract is 230mg Vc/g; the clearance rate to ABTS free radicals is 250mg Vc/g; the reducing power FRAP is 550mg Vc/g.
Further, the mass volume ratio of the longan pulp powder to the ethanol in the step (2) is 1: 10.
Further, the amount of ethyl acetate added in step (5) is 5 to 6 times the volume of the concentrate a.
Compared with the prior art, the invention has the following beneficial effects:
1. the invention adopts an alcohol extraction method to prepare a longan pomace polyphenol crude extract, and adopts ethyl acetate to extract to obtain longan polyphenol. The polyphenol component of longan pomace is determined by UPLC-QqQ-MS/MS analysis. Through a mouse experiment, the longan pomace polyphenol is determined to have the effect of preventing mouse non-alcoholic steatohepatitis induced by high-fat diet.
2. The longan pomace polyphenol extract provided by the invention has clear polyphenol composition: gallic acid, procyanidin B, epicatechin, procyanidin A2, syringic acid, 4-hydroxycinnamic acid, poncirin, ferulic acid, rutin, phlorizin and 6-methoxynaringenin.
3. The longan pomace polyphenol extract provided by the invention has the functions of obviously reducing blood fat and liver lipid and improving liver inflammation, so that the longan pomace polyphenol extract can be used as a preparation for preventing NASH.
4. The longan pomace polyphenol extract provided by the invention has the effect of increasing LXR and PPAR alpha expression, so that the longan pomace polyphenol extract can play a role in reducing blood fat by regulating and controlling the expression of genes related to lipid catabolism and transportation, and has a clear lipid-reducing mechanism.
Drawings
FIG. 1 is a high performance liquid chromatogram of the composition of a longan pomace polyphenol extract;
FIG. 2 is a graph of longan pomace polyphenol extract reducing weight and white fat cell size in high fat diet-induced NASH mice in accordance with the present invention;
FIG. 3 is a graph of serum and liver lipids of mice induced by NASH diet improved by longan pomace polyphenol extract of the invention;
FIG. 4 is a graph showing the effect of the longan pomace polyphenol extract on the expression of genes related to lipid metabolism.
Detailed Description
The process of the invention is described in detail below with reference to specific examples and illustrative figures. Wherein, the longan pomace polyphenol extract prepared by the method can be abbreviated as LPPE.
Preparation of longan pomace polyphenol extract
Example 1
Application of longan pomace polyphenol extract in preparation of medicine for preventing and treating non-alcoholic steatohepatitis is provided.
The longan pomace polyphenol extract is prepared by the following method:
(1) drying the longan fruit residues at 45 ℃ for 48h, and crushing by using an ultra-high speed crusher to obtain longan fruit residue powder for later use;
(2) adding the longan fruit residue powder into 80 mass percent ethanol according to the mass volume ratio of 1:10, and homogenizing for 2min at the rotating speed of 5000 rad/min; extracting with ultrasonic wave for 30min, and collecting filtrate;
(3) extracting the above residue for 2 times, and collecting filtrates respectively;
(4) combining the filtrates collected in step (2) and step (3), and concentrating the collected filtrates at 40 deg.C under 10mbar under reduced pressure to viscous to obtain concentrated solution A;
(5) adding ethyl acetate into the concentrated solution A, wherein the addition amount of the ethyl acetate is 5 times of the volume of the concentrated solution A, stirring for 20min, and then placing the mixture in a separating funnel for standing until obvious layering occurs;
(6) concentrating the upper layer at 40 deg.C under 10mbar under reduced pressure to obtain concentrated solution B;
(7) and (3) drying the concentrated solution B in vacuum freeze drying to obtain the longan pomace polyphenol extract which is in powder form.
Wherein, the medicine is an oral preparation.
Wherein the medicine is tablet, microcapsule, pill or powder, and the dosage is 200 mg/kg.
The total polyphenol content of the longan pomace polyphenol extract is not lower than 700mg of gallic acid equivalent/g, the gallic acid content in the main component is not lower than 20mg/g, the procyanidine content is not lower than 25mg/g, the epicatechin content is not lower than 7mg/g, and the phlorizin content is not lower than 300 mg/g. The removal rate of DPPH free radical by the longan pomace polyphenol extract is 230mg Vc/g; the clearance rate to ABTS free radicals is 250mg Vc/g; the reducing power FRAP is 550mg Vc/g.
Example 2
Application of longan pomace polyphenol extract in preparation of medicine for preventing and treating non-alcoholic steatohepatitis is provided.
The longan pomace polyphenol extract is prepared by the following method:
(1) drying longan fruit residues at 55 ℃ for 36h, and crushing by using an ultra-high speed crusher to obtain longan fruit residue powder for later use;
(2) adding the longan pulp powder into 80 mass percent ethanol according to the mass-to-volume ratio of 1:10, and homogenizing for 2min at the rotating speed of 8000 rad/min; ultrasonic-assisted extraction for 30min, and collecting filtrate;
(3) extracting the above residue for 2 times, and collecting filtrates respectively;
(4) combining the filtrates collected in the steps (2) and (3), and concentrating the collected filtrates at 45 ℃ and under 100mbar under reduced pressure to obtain a concentrated solution A;
(5) adding ethyl acetate into the concentrated solution A, wherein the addition amount of the ethyl acetate is 6 times of the volume of the concentrated solution A, stirring for 30min, and then placing the mixture into a separating funnel for standing until obvious layering occurs;
(6) concentrating the supernatant under reduced pressure at 45 deg.C and 100mbar to obtain concentrated solution B;
(7) and (3) drying the concentrated solution B in vacuum freeze drying to obtain the longan pomace polyphenol extract which is in powder form.
Wherein, the medicine is an oral preparation.
Wherein the medicine is tablet, microcapsule, pill or powder, and the dosage is 200 mg/kg.
Wherein the total polyphenol content of the longan pomace polyphenol extract is not less than 700mg gallic acid equivalent/g, the gallic acid content in the main components is not less than 20mg/g, the procyanidin content is not less than 25mg/g, the epicatechin content is not less than 7mg/g, and the phlorizin content is not less than 300 mg/g. The removal rate of DPPH free radical by the longan pomace polyphenol extract is 230mg Vc/g; the clearance rate to ABTS free radicals is 250mg Vc/g; the reducing power FRAP is 550mg Vc/g.
Example 3
Application of longan pomace polyphenol extract in preparation of medicine for preventing and treating non-alcoholic steatohepatitis is provided.
The longan pomace polyphenol extract is prepared by the following method:
(1) drying the longan fruit residues at 50 ℃ for 40h, and crushing by using an ultra-high speed crusher to obtain longan fruit residue powder for later use;
(2) adding the longan pulp powder into 80% ethanol by mass according to the mass-to-volume ratio of 1:10, and homogenizing at the rotating speed of 6000rad/min for 2 min; ultrasonic-assisted extraction for 30min, and collecting filtrate;
(3) extracting the above residue for 2 times, and collecting filtrates respectively;
(4) combining the filtrates collected in step (2) and step (3), and concentrating the collected filtrates at 42 deg.C under 50mbar under reduced pressure to obtain concentrated solution A;
(5) adding ethyl acetate into the concentrated solution A, wherein the addition amount of the ethyl acetate is 6 times of the volume of the concentrated solution A, stirring for 30min, and then placing the mixture into a separating funnel for standing until obvious layering occurs;
(6) concentrating the upper layer at 42 deg.C under 50mbar under reduced pressure to obtain concentrated solution B;
(7) and (3) drying the concentrated solution B in vacuum freeze drying to obtain the longan pomace polyphenol extract which is in powder form.
Wherein, the medicine is an oral preparation.
Wherein the medicine is tablet, microcapsule, pill or powder, and the dosage is 200 mg/kg.
The total polyphenol content of the longan pomace polyphenol extract is not lower than 700mg of gallic acid equivalent/g, the gallic acid content in the main component is not lower than 20mg/g, the procyanidine content is not lower than 25mg/g, the epicatechin content is not lower than 7mg/g, and the phlorizin content is not lower than 300 mg/g. The removal rate of DPPH free radical by the longan pomace polyphenol extract is 230mg Vc/g; the clearance rate to ABTS free radicals is 250mg Vc/g; the reducing power FRAP is 550mg Vc/g.
Secondly, component analysis of the longan pomace polyphenol extract prepared by the invention
A certain amount of LPPE powder was weighed, purified water was added to prepare a solution having a concentration of 1mg/mL, and after passing through a 0.22 μm microporous membrane, analysis was performed by an ultra-high pressure liquid chromatograph (UPLC, agilent, ca, usa) equipped with an electrospray ionization source (ESI) and a triple quadrupole mass spectrometer (6460QqQ-MS, agilent, ca, usa). ZORBAX Eclipse Plus C18 column (100 mm. times.2.1 mm i.d.,1.8 μm, Agilent, USA) was used to isolate compounds. The mobile phase consisted of a 0.1% aqueous formic acid solution (A) and a gradient of methanol with 0.1% formic acid (B) at a flow rate of 0.2 mL/min. The sample was taken in an amount of 5. mu.L, and the column temperature was 35 ℃. The gradient elution was set as follows: 0-10min, 100% to 20% A; 10-11min, 20% A; 11-12min, 20% to 100% A. Fig. 1 is a high performance liquid chromatogram of the composition of the longan pomace polyphenol extract, as shown in fig. 1, the main components of the longan pomace polyphenol are gallic acid, procyanidin B, epicatechin, procyanidin a2, syringic acid, 4-hydroxycinnamic acid, poncirin, ferulic acid, rutin, phlorizin and 6-methoxynaringenin.
Thirdly, the application of the longan pomace polyphenol extract prepared by the invention in the prevention and treatment of NASH (NASH)
3.1) animal Experimental design and methods
30 healthy male C57BL/6J mice (22 g. + -.1 g) were randomized into 3 groups of 10 mice each after 1 week of acclimatization, namely a control group (Chow), a model group (HFD), and an LPPE group (HFD + 0.2% LPPE). The Chow group was given a general diet (fat calorie of 10%), the HFD group was given a high fat diet (fat calorie of 60%), the LPPE group was given a high fat diet with the addition of 0.2% LPPE, and the body weight and food intake of the mice were recorded during the administration. During the experiment (12 weeks), mice were free to drink water and fasted for 12h after the end of the experiment, and anaesthesia dissection and tissue sample collection were performed. Fixing part of the liver in 4% paraformaldehyde solution for subsequent paraffin section and H & E staining; quick freezing part of liver with liquid nitrogen, storing at-80 deg.C for preparing frozen slice and measuring lipid, gene and protein level;
mouse blood was centrifuged at 3000 Xg for 15min and the upper serum was collected. Serum Total Cholesterol (TC), total Triglyceride (TG), low density lipoprotein cholesterol (LDL-c) and high density lipoprotein cholesterol (HDL-c) levels were measured using a fully automated biochemical analyzer.
Weighing 50mg of liver tissue, homogenizing with 0.5mL of tissue lysate, adding 1mL of chloroform for extraction, air-drying to remove organic solvent, and determining according to the instruction of the total cholesterol and triglyceride quantitative analysis kit.
The fixed liver tissue is embedded in paraffin, cut into 5-6 μm slices, stained with hematoxylin-eosin, mounted, and examined under microscope. The liver tissue stored at-80 ℃ was taken out, frozen sections were prepared, stained with oil red O reagent, and mounted for observation under a microscope.
3.2) results of animal experiments
FIG. 2 is a graph of the longan pomace polyphenol extract of the present invention reducing high fat diet-induced weight and white fat cell size in NASH mice, wherein (A) weight (g) before and after the mice experiment; (B) mouse white fat cells were H & E stained (× 200). Mice in Chow group were given general diet (fat calories of 10%), HFD group was given high fat diet (fat calories of 60%), LPPE group was given high fat diet with 0.2% LPPE added, and mice were allowed to take water freely during the experiment. Results are expressed as mean ± standard deviation (n ═ 8), and the letters marked on the same color histogram differ significantly (P < 0.05). As can be seen from fig. 2, the mice continuously ingested the high fat diet for 12 weeks, resulting in a significant increase in body weight and an increase in white fat cells. However, there was a significant reduction in body weight in mice given the addition of 0.2% LPPE, as well as a reduction in leukocyte size.
FIG. 3 is a graph of serum and liver lipids of mice with high lipid diet-induced NASH by polyphenol extract from longan pomace of the present invention, wherein (A) serum cholesterol (TC), Triglycerides (TG), high density lipoprotein cholesterol (HLD-c) and low density lipoprotein cholesterol (LDL-c) levels; (B) TG content in liver; (C) TC content in the liver; (D) liver H & E staining (× 200); (E) liver oil red O staining (× 200). Mice in Chow group were given general diet (fat calorie of 10%), HFD group was given high fat diet (fat calorie of 60%), LPPE group was given high fat diet with 0.2% LPPE added, and mice were allowed to take water freely during the experiment. Results are expressed as mean ± standard deviation (n-8). Different letters of the same index indicate significant difference (P < 0.05). As can be seen from fig. 3, serum Total Cholesterol (TC), total Triglycerides (TG), low density lipoprotein cholesterol (LDL-c) and high density lipoprotein cholesterol (HDL-c) were significantly increased after mice continuously ingesting high-fat diet for 12 weeks, as compared to the control group (Chow group). However, 0.2% LPPE significantly reduced serum TC, TG and LDL-c in obese mice. Fig. 3B shows that high fat diet significantly increased mouse liver TG and TC, while 0.2% LPPE also significantly decreased HFD-induced TG and TC in obese mice. In addition, H & E staining indicated that unequal-size fat vacuoles, blurred cell boundaries, nuclear fragmentation or lysis, with little inflammatory cell infiltration were visible in the hepatocyte cytoplasm of mice in the HFD group NASH. The hepatic cells were significantly reduced in fat vacuoles after LPPE treatment, with few inflammatory cells (3C). Finally, oil red O staining results indicated that there was a large accumulation of red lipid droplets in hepatocytes of HFD group mice, whereas LPPE treatment significantly reduced lipid droplet content (3D). The results show that the longan pomace polyphenol extract can obviously reduce mouse hyperlipidemia and liver lipid accumulation caused by high-fat diet induction and alleviate liver inflammation.
FIG. 4 is a graph showing the effect of polyphenol extract from longan pomace on the expression of genes related to lipid metabolism, wherein (A) LXR; (B) FAS; (C) PPAR α; (D) CYP27a 1; (E) CYP7a 1; (G) AMPK. Mice in Chow group were given general diet (fat calorie of 10%), HFD group was given high fat diet (fat calorie of 60%), LPPE group was given high fat diet with 0.2% LPPE added, and mice were allowed to take water freely during the experiment. Results are expressed as mean ± standard deviation (n-5). Different letters indicate significant difference (P < 0.05). As can be seen from fig. 4: LPPE Liver X Receptor (LXR) and downstream FAS, CYP27A1 and CYP7A1 gene expression can increase PPAR alpha and AMPK expression, inhibit fatty acid synthesis, promote fatty acid oxidation, and improve lipid metabolism.
Finally, the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all of them should be covered in the claims of the present invention.
Claims (10)
1. Application of longan fruit residue polyphenol extract in preparing medicine for preventing and treating non-alcoholic steatohepatitis is provided.
2. The use of the longan pomace polyphenol extract as claimed in claim 1 in the preparation of a medicament for preventing and treating non-alcoholic steatohepatitis, wherein the longan pomace polyphenol extract is in a powder form.
3. The use of the longan pomace polyphenol extract as claimed in claim 1 in the preparation of a medicament for preventing and treating non-alcoholic steatohepatitis, wherein the medicament is an oral preparation.
4. The use of the longan pomace polyphenol extract as claimed in claim 1 in the preparation of a medicament for preventing and treating non-alcoholic steatohepatitis, wherein the medicament is a tablet, a microcapsule, a pill or a powder.
5. The use of the longan pomace polyphenol extract as claimed in claim 4 in the preparation of a medicament for preventing and treating non-alcoholic steatohepatitis, wherein the dosage of the medicament is 200 mg/kg.
6. The application of the longan pomace polyphenol extract in preparing the medicine for preventing and treating the non-alcoholic steatohepatitis as claimed in claim 5, wherein the preparation method of the longan pomace polyphenol extract comprises the following steps:
(1) drying longan fruit residues at 45-55 deg.C for 36-48h, and pulverizing with ultra-high speed pulverizer to obtain longan fruit residue powder;
(2) adding the longan fruit residue powder into 80 mass percent ethanol, and homogenizing for 2min at the rotation speed of 5000 plus 8000 rad/min; ultrasonic-assisted extraction for 30min, and collecting filtrate;
(3) extracting the above residue for 2 times, and collecting filtrates respectively;
(4) combining the filtrates collected in step (2) and step (3), and concentrating the collected filtrates at 40-45 deg.C under 10-100mbar under reduced pressure to obtain concentrated solution A;
(5) adding ethyl acetate into the concentrated solution A, stirring for 20-30min, and standing in a separating funnel until obvious layering occurs;
(6) concentrating the supernatant at 40-45 deg.C under 10-100mbar under reduced pressure to obtain concentrated solution B;
(7) and (3) drying the concentrated solution B in vacuum freeze drying to obtain the longan pomace polyphenol extract.
7. The use of the polyphenol extract from longan pomace as defined in claim 6 for preparing a medicament for preventing and treating non-alcoholic steatohepatitis, wherein the total polyphenol content of the polyphenol extract from longan pomace is not less than 700mg gallic acid equivalent/g.
8. The use of the longan pomace polyphenol extract as claimed in claim 6 in the preparation of a medicament for preventing and treating non-alcoholic steatohepatitis, wherein the longan pomace polyphenol extract has a DPPH free radical scavenging rate of 230 mgVc/g; the clearance rate to ABTS free radicals is 250 mgVc/g; the reducing power FRAP is 550 mgVc/g.
9. The application of the longan pomace polyphenol extract in preparing the medicine for preventing and treating nonalcoholic steatohepatitis as claimed in claim 6, wherein the mass-to-volume ratio of the longan pomace powder to the ethanol in the step (2) is 1: 10.
10. The use of the longan pomace polyphenol extract as claimed in claim 6 in the preparation of a medicament for preventing and treating nonalcoholic steatohepatitis, wherein the amount of ethyl acetate added in step (5) is 5-6 times the volume of the concentrated solution A.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210575399.0A CN115025078B (en) | 2022-05-24 | 2022-05-24 | Application of longan pomace polyphenol extract in preparation of medicine for preventing and treating non-alcoholic steatohepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210575399.0A CN115025078B (en) | 2022-05-24 | 2022-05-24 | Application of longan pomace polyphenol extract in preparation of medicine for preventing and treating non-alcoholic steatohepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115025078A true CN115025078A (en) | 2022-09-09 |
| CN115025078B CN115025078B (en) | 2024-02-23 |
Family
ID=83121256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210575399.0A Active CN115025078B (en) | 2022-05-24 | 2022-05-24 | Application of longan pomace polyphenol extract in preparation of medicine for preventing and treating non-alcoholic steatohepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115025078B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920830A (en) * | 2012-11-28 | 2013-02-13 | 华南师范大学 | Method for effectively extracting polyphenol from Longan seed |
| CN104547206A (en) * | 2014-12-23 | 2015-04-29 | 东北大学 | Longan pericarp extract as well as extracting method, composition and application thereof |
| US20180296627A1 (en) * | 2017-04-10 | 2018-10-18 | Tci Co., Ltd | Method for modulating the expression of the srebp-1c, acc, and scd-1 proteins using longan pericarp extract |
| CN110787240A (en) * | 2018-08-01 | 2020-02-14 | 大江生医股份有限公司 | Application of longan shell extract in preparing composition for regulating and controlling SREBP-1c, ACC and SCD-1 proteins |
-
2022
- 2022-05-24 CN CN202210575399.0A patent/CN115025078B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920830A (en) * | 2012-11-28 | 2013-02-13 | 华南师范大学 | Method for effectively extracting polyphenol from Longan seed |
| CN104547206A (en) * | 2014-12-23 | 2015-04-29 | 东北大学 | Longan pericarp extract as well as extracting method, composition and application thereof |
| US20180296627A1 (en) * | 2017-04-10 | 2018-10-18 | Tci Co., Ltd | Method for modulating the expression of the srebp-1c, acc, and scd-1 proteins using longan pericarp extract |
| CN110787240A (en) * | 2018-08-01 | 2020-02-14 | 大江生医股份有限公司 | Application of longan shell extract in preparing composition for regulating and controlling SREBP-1c, ACC and SCD-1 proteins |
Non-Patent Citations (8)
Also Published As
| Publication number | Publication date |
|---|---|
| CN115025078B (en) | 2024-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kao et al. | Polyphenolic extract from Hibiscus sabdariffa reduces body fat by inhibiting hepatic lipogenesis and preadipocyte adipogenesis | |
| RU2695806C2 (en) | Pharmaceutical composition containing silybin and vitamin e | |
| CN104644882B (en) | Callicarpa nudiflora extract containing phenylethanoid glycosides and preparation method thereof | |
| CN106474145A (en) | Application in preparation preventing and treating alcoholic liver injury medicine and food for the Polysaccharides from Leaves of Moringa oleifera | |
| CN105168303B (en) | Application of the Viburnum opulus Linn. var. calvescens (Rehd.) Hara f. calvescens alcohol extract in preparation treatment nonalcoholic fatty liver drug | |
| CN113999272A (en) | Preparation method and application of melissoside | |
| WO2020091265A1 (en) | Composition comprising elderberry extract as effective component for preventing, treating, or alleviating male climacteric syndrome | |
| CN112426442A (en) | Seabuckthorn total flavone extract and application thereof | |
| KR101227737B1 (en) | A composition comprising Ligularia stenocephala extract, fractions thereof or compounds isolated from Ligularia stenocephala extract and fractions thereof having peroxinitrite-scavenging activity | |
| CN104873616B (en) | Application of the litchi rind polyphenol in the medicine or health products that reduce liver tg is prepared | |
| CN115025078A (en) | Application of longan pomace polyphenol extract in preparation of medicine for preventing and treating non-alcoholic steatohepatitis | |
| KR101204415B1 (en) | Compositions for Preventing or Treating Obesity, Hyperlipidemia or Fatty Liver | |
| CN113694104B (en) | Traditional Chinese medicine composition with protection effect on chemical liver injury and liver regeneration promotion function, preparation method and application thereof | |
| KR20150046427A (en) | A pharmaceutical composition for preventing and treating nonalcoholic fatty liver disease comprising extraction fraction with enhanced gincenoside rb1 from panax ginseng as an active ingredient | |
| CN109876088B (en) | Natural hypoglycemic preparation capable of lowering blood sugar by regulating intestinal flora balance | |
| CN104688723B (en) | Application of icaritin in preparation of medicine for treating anemia | |
| CN113350390A (en) | Total sesquiterpene lactone of saussurea involucrata, preparation method and pharmaceutical application thereof | |
| CN106822095A (en) | A kind of medicine and its application in pharmacy for preventing and treating fatty liver and obesity | |
| KR101293835B1 (en) | Composition comprising the combined extract of Astragalus membranaceus Bunge and Plantago asiatica for preventing and treating obesity | |
| CN110840950A (en) | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury | |
| CN109758492A (en) | A kind of chrysanthemum total flavone and its preparation method and application | |
| CN104922271B (en) | Application of the litchi rind polyphenol in the medicine or health products that reduce hepatic cholesterol is prepared | |
| CN116693711B (en) | Polygonum multiflorum polysaccharide, extraction method and application thereof | |
| CN117838758A (en) | Application of weeping forsythia leaf extract in preparation of medicine for preventing and treating non-alcoholic fatty liver disease | |
| CN115040476B (en) | Compound blood pseudo-ginseng hypoglycemic oral liquid as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |